cenplacel-l
Cell therapyexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01261403)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, desensitized
immunity, desensitized
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107867 ↗
Also known as
- cenplacel-l
- cenplacel-l
- pda001
- pda001
- pda-002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02552277 | Phase 2 | Oct 27, 2015 | Celgene |
| NCT02460081 | Phase 2 | Jun 1, 2015 | Celgene |
| NCT02264288 | Phase 2 | Oct 23, 2014 | Celgene |
| NCT01859117 | Phase 1 | May 1, 2013 | Celgene |
| NCT01769755 | Phase 1 | Mar 1, 2013 | Celgene |
| NCT01440192 | Phase 1 | Sep 1, 2011 | Celgene |
| NCT01261403 | Phase 2 | Dec 1, 2010 | Celgene |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1